Pharming Group N.V. — Form 6-K Summary
Reporting period: First quarter ended March 31, 2023; preliminary, unaudited results furnished on May 11, 2023. Pharming is a Netherlands-based rare-disease biopharmaceutical company commercializing RUCONEST and launching Joenja (leniolisib).
Business Context and Key Developments
- The FDA approved Joenja on March 24, 2023, as the first and only U.S.-approved treatment for activated PI3Kδ syndrome (APDS) in patients age 12 and older.
- U.S. commercial shipments began in early April. By the reporting date, 23 patients were on paid therapy; initial Joenja revenue is expected to be recorded in the second quarter of 2023.
- RUCONEST remains marketed for acute hereditary angioedema (HAE) attacks. First-quarter shipments were affected by temporary reimbursement disruptions for certain government-insured patients, which management said had subsequently resolved.
Financial Performance and Liquidity
| US$ millions, except per-share data | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Revenue | 42.5 | 46.6 | Down 9% |
| Gross profit | 38.5 | 41.7 | Down 8% |
| Operating profit (loss) | (13.7) | 2.8 | Declined |
| Net profit (loss) | (12.2) | 3.5 | Declined |
| Basic EPS | (US$0.019) | US$0.005 | Declined |
| Operating cash flow | (22.8) | 0.6 | Declined |
- Gross margin was approximately 90% in both periods, based on reported revenue and gross profit.
- Operating expenses increased to US$52.7 million from US$39.8 million, primarily due to Joenja launch preparation and higher payroll expenses associated with business growth.
- Net finance expense was US$2.7 million, compared with net finance income of US$1.8 million in the prior-year quarter.
- Cash and cash equivalents were US$184.8 million at March 31, 2023, down from US$207.3 million at December 31, 2022. Cash and marketable securities, including restricted cash, totaled US$186.2 million.
- Total convertible bonds were approximately US$135.4 million, comprising US$133.6 million non-current and US$1.8 million current balances. Lease liabilities totaled approximately US$35.0 million.
- Operating cash use reflected the quarterly loss and working-capital investments, including increases in inventory and receivables.
Material Changes Versus the Prior Comparable Period
- Revenue decreased by US$4.1 million, primarily because reimbursement disruptions delayed shipments to some government-insured HAE patients.
- Operating profit shifted from a US$2.8 million profit to a US$13.7 million loss as operating expenses rose by US$12.9 million.
- Net results shifted from a US$3.5 million profit to a US$12.2 million loss.
- Operating cash flow declined from US$0.6 million generated to US$22.8 million used.
- Research and development expense increased to US$15.6 million from US$14.9 million; general and administrative expense increased to US$10.0 million from US$7.7 million; marketing and sales expense increased to US$27.1 million from US$17.2 million.
Guidance, Outlook, Risks, and Unusual Items
- Management maintained its expectation for low-single-digit annual RUCONEST revenue growth in 2023, while cautioning that quarterly fluctuations are expected.
- Management expects continued profit pressure during 2023 from Joenja commercialization, launch preparation, pediatric and Japanese development, and exploration of additional leniolisib indications.
- The company expects its existing cash and continued RUCONEST cash generation to fund planned investments. No specific overall 2023 financial guidance was provided.
- Pharming expects a positive EMA CHMP opinion for leniolisib in the second half of 2023, with European authorization approximately two months later. A U.K. filing is planned shortly after a positive CHMP opinion.
- A pediatric trial for APDS patients aged 4 to 11 began in February 2023; a second trial for children aged 1 to 6 is expected to begin in the third quarter.
- Pharming filed for orphan-drug designation in Japan and expected to begin a Japanese APDS trial in the second quarter of 2023.
- The company discontinued further development of its Pompe preclinical asset.
- FDA approval triggered a US$0.5 million milestone payment to another party in the first quarter. The first commercial Joenja sale triggered a US$10 million milestone payment to Novartis in the second quarter. Additional Novartis milestones of up to US$190 million and tiered royalties on leniolisib net sales may become payable.
- Pharming reported full access to its deposits following the Silicon Valley Bank events in March 2023.
- Key risks include reimbursement and market-access delays, regulatory approval and timing, clinical-trial outcomes, commercialization execution, continued operating losses and cash use, milestone and royalty obligations, foreign-exchange movements, and the risks described in the company’s 2022 Annual Report and Form 20-F.
Investor Verification Points
- Verify the number of Joenja patients converted to paid therapy, reimbursement approvals, and reported Joenja revenue in subsequent quarters.
- Assess whether RUCONEST reimbursement disruptions have fully normalized and whether low-single-digit annual growth is achieved.
- Track cash burn, operating expenses, convertible-bond obligations, milestone payments, and royalty commitments.
- Monitor EMA, U.K., Japan, and pediatric regulatory and clinical milestones, including their impact on launch timing and spending.
- Evaluate whether additional leniolisib indications or acquisitions require external financing.
- Confirm subsequent financial statements because the reported first-quarter results were preliminary and unaudited.